Ariadne Launches Pathway Studio® Version 7 – Software for Mechanistic Modeling of Biological Processes and Disease
ROCKVILLE, MD, October 15, 2009 – Ariadne is pleased to announce the release of Pathway Studio® version 7, Desktop Edition. Pathway Studio software is used broadly in Academia and Industry to facilitate research of molecular biology, experimental data analysis, drug discovery and development, and plant genomics research. The new Pathway Studio 7, which includes the Desktop software, ResNet® Mammalian database, and MedScan® Reader software brings many new features, including:
- Regenerated and more robust ResNet Database
- More pathway building and visualization tools
- Improved data and software support for analysis of miRNA
- Next generation of literature extraction technology
- Improved training tools
- New enrichment analysis results data
- Metabolic pathways
- Updated Ariadne Ontology
- Expanded support for import of experimental data
- Expanded entity ID annotation
“With the introduction of the third generation of MedScan technology in Pathway Studio 7”, says David Denny, Product Manager at Ariadne, “we have closed the gap between manual and automated curation of biological relationships, resulting in a significant improvement in ResNet data quality. The ResNet database not only has the broadest range of data, but provides uniform coverage across different biological entities and research areas extracting facts multiple times, enabling scientists to conduct a comprehensive survey in search of the most relevant relationships to their particular area of interest.”
The ResNet 7 Mammalian database has been completely rebuilt, incorporating Ariadne’s latest generation of literature extraction technology and has been curated utilizing our proprietary technology to reduce errors, redundancy, and to improve usability of the database. In addition, the new MedScan Reader incorporates Ariadne’s third-generation of Knowledge Extraction technology software replacing Ariadne’s previous Natural Language Processing engine.
“The new MedScan provides a unique capability for customers to recover facts from literature that are specific to their research, and develop a unique resource,” explains Gabriella Armin, Director of Marketing at Ariadne. “By including profiling data, articles from journals, manually curated facts, and any other type of text documents, our clients are able to work with integrated data and up-to-date findings to make better decisions.”
Ariadne’s Pathway Studio® software enables researchers to model disease, drug and toxicity mechanisms using the vast amounts of published information and then continues to evolve these models by integrating experimental data and in-house data.
“This provides multiple benefits to researchers”, says Armin, “where basic mechanistic models can provide biological insights to complex protein interactions, help develop hypothesis and define experimental designs that are more informative than traditional shotgun approaches. Once defined, these models can then be interrogated to yield associations that lead to potential biomarkers of drug activity, disease progression, disease diagnostics and protein modulation. These models require an integrated knowledgebase of protein (for broad cellular systems biology context) and chemical (for on & off drug target effects) functional information, all of which Pathway Studio contains.”
For more information please contact Ariadne at 240-453-6296 or www.ariadnegenomics.com.
About Ariadne
Ariadne’s (www.ariadnegenomics.com) Pathway Studio software is used worldwide as a comprehensive solution for analyzing and searching pathways and molecular interaction information. Ariadne offers desktop and enterprise editions of Pathway Studio, which are supported by several commercial and publicly available molecular interaction databases including ResNet Mammalian, ResNet Plant, ResNet ChemEffect™, and Prolexys HyNet™. Pathway Studio is powered by MedScan technology, which researchers can use to edit and enhance database content from the current literature and from experimental data.
